三阴性乳腺癌化疗及放疗增敏作用研究进展

三阴性乳腺癌是指雌激素受体、孕激素受体和人表皮生长因子受体2的表达均为阴性的乳腺癌，具有预后差、复发率高、侵袭转移快和死亡率高等特点。化疗是临床治疗三阴性乳腺癌的主要手段之一，但随着治疗的进展，三阴性乳腺癌患者易产生不同程度的耐药反应，从而使治疗效果大大降低。因此，寻找有效的增敏靶点和制剂具有十分重要的治疗价值。本文将从三阴性乳腺癌放疗及化疗现状，已知的增敏靶点研究进展以及具有潜在增敏作用靶点的研究进展方面予以综述，旨在为三阴性乳腺癌化疗提供借鉴和参考。

Research progress of sensitization of chemotherapy and radiotherapy in triple-negative breast cancer

Triple-negative breast cancer refers to breast cancer with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2). It has the characteristics of poor prognosis, high recurrence rate, rapid invasion and metastasis, and high mortality. Chemotherapy is one of the main means of clinical treatment for triple-negative breast cancer, but with the progress of treatment, triple-negative breast cancer patients are prone to produce different degrees of drug resistance, which greatly reduces the therapeutic effect. Therefore, it is of great importance to find effective targets and preparations for sensitization. This article will review the current status of triple negative breast cancer radiotherapy and chemotherapy, the research progress of known sensitization targets and potential sensitization targets, in order to provide reference for triple negative breast cancer chemotherapy.